Complications of Myelofibrosis Beyond Splenomegaly
Myelofibrosis causes life-threatening complications including leukemic transformation (approaching 20% in the first 10 years), severe cytopenias requiring transfusions, extramedullary hematopoiesis in atypical sites, thrombohemorrhagic events, portal hypertension with variceal bleeding, debilitating constitutional symptoms, and shortened survival. 1
Major Complications by Category
Hematologic Complications
Severe anemia is common and often requires frequent RBC transfusions, with poor post-transfusion increments due to marked splenomegaly. Severe thrombocytopenia and neutropenia also occur frequently. 1
Leukemic transformation represents a critical mortality risk, with approximately 20% of patients progressing to acute leukemia within the first 10 years of disease. This is one of the primary causes of death in myelofibrosis. 1
Hepatic Complications
Portal hypertension develops in 3-18% of patients, driven by:
- Intrahepatic sinusoidal infiltration from extramedullary hematopoiesis
- Splenic hyperdynamic circulation
- Splanchnic vein thrombosis 2
This leads to variceal bleeding and ascites, which can be life-threatening and may require splenectomy in refractory cases. 1
Extramedullary Hematopoiesis (EMH)
EMH occurs in atypical sites beyond the liver and spleen, causing organ-specific complications:
- Thoracic involvement (26%): Pulmonary hypertension, pleural effusions, dyspnea 3, 4
- Abdominopelvic masses (28%): Abdominal pain, bowel obstruction 3
- Spinal cord compression: From vertebral column involvement, requiring urgent radiation therapy 1
- Cutaneous lesions (13%): Skin tumors from hematopoietic infiltration 3
- Intracranial hypertension: From CNS involvement 4
EMH signals advanced disease with dismal prognosis—mortality reaches 38% with median follow-up of only 5 months in symptomatic cases. 3
Thrombohemorrhagic Complications
Both thrombosis and bleeding occur due to hemostatic dysfunction:
- Splanchnic vein thrombosis often precedes overt MF diagnosis, with JAK2V617F detected in a substantial proportion 2
- Major bleeding events, particularly gastrointestinal 1, 4
Constitutional Symptoms
Profound systemic symptoms severely impact quality of life:
- Fatigue and cachexia
- Weight loss
- Pruritus
- Night sweats
- Low-grade fever
- Bone and joint pain
- Recurrent gout 1
These symptoms result from aberrant cytokine production and contribute significantly to morbidity. 1
Hepatosplenomegaly-Related Complications
Beyond splenomegaly itself, marked hepatosplenomegaly causes:
- Early satiety
- Severe abdominal discomfort
- Changes in bowel habits
- Painful splenic infarcts
- Compromised mobility and movement 1
Clinical Pitfalls
Do not overlook atypical EMH sites—CT/MRI showing characteristic lobulated masses with T2 hypointensity should prompt biopsy confirmation showing trilineage hematopoiesis with atypical megakaryocytes (CD61+). 3
Severe thrombocytopenia is a marker of impending leukemic transformation, not just a cytopenia to manage—it signals the need for urgent transplant evaluation in eligible patients. 1
Marked leukocytosis or thrombocytosis requires cytoreduction with hydroxyurea to prevent thrombotic complications. 1
Prognostic Impact
Shortened survival is the overarching complication, with common fatal outcomes including:
- Leukemic transformation
- Thrombohemorrhagic events
- Organ failure from EMH
- Infections 4
The presence of atypical EMH, transfusion-dependent anemia, peripheral blood blasts >2%, adverse cytogenetics, or high-risk mutations (ASXL1, EZH2, IDH1/IDH2, SRSF2) indicates aggressive disease requiring consideration for allogeneic stem cell transplantation in eligible patients. 5, 3